MTM(SH:688029)2021-10-27 16:00Financial Performance - The company achieved operating revenue of RMB 514.23 million in Q3 2021, representing a year-on-year increase of 42.63%[3] - Net profit attributable to shareholders was RMB 105.24 million, up 11.28% year-on-year, while the net profit excluding non-recurring gains and losses was RMB 72.50 million, an increase of 32.07%[3] - The cumulative operating revenue for the year-to-date reached RMB 1.39 billion, reflecting a growth of 49.19% compared to the same period last year[6] - Operating profit for the third quarter of 2021 was ¥301,726,860.66, compared to ¥226,039,734.98 in the third quarter of 2020, reflecting an increase of about 33.4%[22] - Net profit attributable to shareholders of the parent company for the first three quarters of 2021 was ¥248,528,608.69, up from ¥208,433,126.83 in the same period of 2020, indicating a growth of approximately 19.2%[22] - The company reported a net profit of CNY 734,163,663.08 for the period, compared to CNY 565,639,054.39 in the previous year, indicating a growth of approximately 30.0%[20] Research and Development - Research and development expenses totaled RMB 41.99 million in Q3 2021, marking a 53.74% increase year-on-year, and accounted for 8.17% of operating revenue[5] - Research and development expenses for the first three quarters of 2021 totaled ¥101,025,381.15, compared to ¥64,869,677.85 in the same period of 2020, representing a rise of approximately 55.5%[21] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 3.57 billion, a 14.90% increase from the end of the previous year[5] - As of September 30, 2021, the total assets of the company reached CNY 3,567,958,940.86, an increase from CNY 3,105,227,148.67 at the end of 2020, representing a growth of approximately 14.9%[20] - The total liabilities of the company were CNY 690,152,091.62, compared to CNY 441,592,548.79 in the previous year, which is an increase of approximately 56.2%[19] - Total liabilities reached ¥441,592,548.79, an increase of ¥21,344,967.41 from ¥462,937,516.20[28] - The company's equity attributable to shareholders reached CNY 2,827,457,320.63, up from CNY 2,610,944,909.21, representing an increase of about 8.3%[20] Cash Flow - The company reported a net cash flow from operating activities of RMB 176.77 million for the year-to-date, up 45.54% year-on-year[5] - The company reported a net cash flow from operating activities of ¥176,770,982.80 for the first three quarters of 2021, compared to ¥121,454,595.77 in the same period of 2020, marking an increase of about 45.6%[25] - The company achieved a total cash inflow from investment activities of ¥2,234,762,524.59 in the first three quarters of 2021, compared to ¥1,846,169,446.79 in the same period of 2020, reflecting an increase of about 21.0%[25] Market Expansion and Product Development - The sales of hemostatic and closure products, as well as EME/ESD and ablation products, increased by RMB 116 million, a year-on-year growth of 51.38% in Q3 2021[9] - The company plans to continue focusing on regional marketing strategies to drive market expansion and product sales growth[9] - The company has expanded its product offerings with new approvals, such as the Sterile Sphincterotome in Canada on July 2, 2021[15] - The company has a total of 20 new product registrations in various countries, indicating a strong pipeline for future growth[14] - The company is actively involved in product registration changes, with several products transitioning from Class II to Class III in Brazil[15] - The company is focusing on expanding its product line, with new sterile devices approved in Kenya and Saudi Arabia[15] - The company is committed to innovation, as evidenced by the introduction of new medical devices like the Tracheal Stent System in the United States[15] Shareholder Information - The top ten unrestricted shareholders include Shanghai Gao Yi Asset Management with 1,622,000 shares, China Bank with 1,541,656 shares, and China Construction Bank with 1,199,953 shares[12] - The company has highlighted the importance of monitoring shareholder relationships, particularly with entities linked to its major shareholders[13] Financial Adjustments and Standards - The company adopted the new leasing standards effective January 1, 2021, with no significant impact on financial status[30] - The company has adjusted financial statement items due to the new leasing standards without affecting comparable period information[30]